All In Biotech

NDA 019715 · Mylan Spclt Viatris

Dipentum

Olsalazine Sodium · Oral

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1990

Jul 31, 1990

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2

1 Phase 3, 0 recruiting

FAERS reports

197

146 serious, 11 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 15, 2026.

DIPENTUM is indicated for the maintenance of remission of ulcerative colitis in adult patients who are intolerant of sulfasalazine. DIPENTUM is an aminosalicylate indicated for the maintenance of remission of ulcerative colitis in adult patients who are intolerant of sulfasalazine. ( 1 )

Mechanism: Upon reaching the colon, colonic bacteria convert olsalazine into 5‑aminosalicylic acid (5-ASA or mesalazine). The mechanism of action of 5-ASA (mesalamine) is not fully understood, but appears to be a topical anti-inflammatory effect on colonic epithelial cells. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways (i.e., prostanoids) and through the lipoxygenase pathways (i.e., leukotrienes and hydroxyeicosatetraenoic acids) is increased in patients with ulcerative colitis, and it is possible that mesalamine diminishes inflammation by blocking...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 31, 1990 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
  • DIPENTUM · OLSALAZINE SODIUM 250MG · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Olsalazine" as an intervention, any sponsor and status, largest first.

All 2 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • colitis ulcerative19
  • diarrhoea14
  • drug ineffective12
  • off label use11
  • fatigue9
  • pain8
  • pain in extremity7
  • pruritus7
  • pyrexia7
  • abdominal pain6
  • anxiety6
  • arthralgia6

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200414
200518
200611
20078
200811
200918
201014
201118
20129
201310
20149
20159
20167
20174
20184
20195
20206
202110
20223
20233
20243
20252
20261

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Dipentum (Olsalazine Sodium)

2024 spending

$2.9M

Beneficiaries

194

1,345 claims

Per beneficiary

$14,808

$14.55 per unit

View as table
YearSpending
2020$3,782,856
2021$3,090,782
2022$3,016,255
2023$2,854,712
2024$2,872,707

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 61 on PubMed

Sponsor: Mylan Spclt Viatris

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.